A pharmacovigilance study of FDA adverse events for sugammadex
Authors:
- 15 June 2024
- journal article
- research article
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 97, 111509
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 34 references indexed in Scilit:
- The effect of sugammadex on patient morbidity and quality of recovery after general anaesthesia: a systematic review and meta-analysisBritish Journal of Anaesthesia, 2023
- Reversal of neuromuscular block by sugammadex is associated with less postoperative respiratory dysfunction in the PACU compared with neostigmine: a retrospective studyBritish Journal of Anaesthesia, 2023
- Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseeClinicalMedicine, 2023
- Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance systemeClinicalMedicine, 2022
- Association between choice of reversal agent for neuromuscular block and postoperative pulmonary complications in patients at increased risk undergoing non-emergency surgery: STIL-STRONGER, a multicentre matched cohort studyBritish Journal of Anaesthesia, 2022
- Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive AssociationsDrug Safety, 2020
- Sugammadex Administration to Facilitate Timely Neurologic Examination in the Traumatic Brain Injury PatientNeurocritical Care, 2020
- Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgeryJournal of Anesthesia, 2011
- A Bayesian neural network method for adverse drug reaction signal generationEuropean Journal of Clinical Pharmacology, 1998
- Serum sickness-like reactions to cefaclorJournal of Clinical Epidemiology, 1992